{"id":{"repo_id":"mcmaster","oai_identifier":"oai:macsphere.mcmaster.ca:11375/12901"},"canonical_url":"https://search.ndltd.org/etd/mcmaster/oai:macsphere.mcmaster.ca:11375/12901","repository":{"repo_id":"mcmaster","name":"McMaster University","base_url":"https://macsphere.mcmaster.ca/server/oai/request"},"display":{"title":"EFFECTS OF VALPROIC ACID ON EXPRESSION OF THE MELATONIN RECEPTORS MT1 AND MT2, AND THE NEUROTROPHIC FACTORS BDNF AND GDNF IN VIVO","abstract":"<p>Valproic acid (VPA) is clinically utilized as an anti-convulsant and mood stabilizer, though its mechanism of action has not been fully elucidated.<strong> </strong>Evidence suggests an interaction between VPA and the melatonergic system as VPA up-regulated the melatonin MT<sub>1</sub> receptor subtype in rat C6 glioma cells. To determine if the observed effects can translate to an <em>in vivo </em>model, we investigated the effects of chronic VPA administration in a rat model on the expression of MT<sub>1</sub> and MT<sub>2</sub> receptors in the hippocampus. We also investigated the effect of chronic VPA treatment on the expression of the neurotrophic factors BDNF and GDNF in the rat hippocampus and striatum.</p> <p>(1) Animals were separated into two groups with the experimental group receiving VPA (4 mg/mL) for 17 days, and the control receiving vehicle. The hippocampus was dissected and MT<sub>1</sub>, MT<sub>2</sub>, BDNF and GDNF mRNA were analyzed with RT-PCR. (2) Animals were separated into three groups with the first group receiving VPA (4 mg/mL), the second receiving VPA (3 mg/mL) for 16 days, and the control receiving vehicle. MT<sub>2</sub> mRNA in the hippocampal subregions were analyzed with in situ hybridization.</p> <p>VPA induced the expression of MT<sub>1</sub> and MT<sub>2</sub> mRNA in the hippocampus in the experimental group compared to the control group. VPA also increased MT<sub>2</sub> mRNA expression in the subregions of the hippocampus. Additionally, BDNF and GDNF mRNA expression were increased in the VPA treatment group.</p> <p>These findings raise the interesting question of whether the diverse clinical effects of VPA involve an interaction with the melatonergic system.</p>","abstract_html":"&lt;p&gt;Valproic acid (VPA) is clinically utilized as an anti-convulsant and mood stabilizer, though its mechanism of action has not been fully elucidated.&lt;strong&gt; &lt;/strong&gt;Evidence suggests an interaction between VPA and the melatonergic system as VPA up-regulated the melatonin MT&lt;sub&gt;1&lt;/sub&gt; receptor subtype in rat C6 glioma cells. To determine if the observed effects can translate to an &lt;em&gt;in vivo &lt;/em&gt;model, we investigated the effects of chronic VPA administration in a rat model on the expression of MT&lt;sub&gt;1&lt;/sub&gt; and MT&lt;sub&gt;2&lt;/sub&gt; receptors in the hippocampus. We also investigated the effect of chronic VPA treatment on the expression of the neurotrophic factors BDNF and GDNF in the rat hippocampus and striatum.&lt;/p&gt; &lt;p&gt;(1) Animals were separated into two groups with the experimental group receiving VPA (4 mg/mL) for 17 days, and the control receiving vehicle. The hippocampus was dissected and MT&lt;sub&gt;1&lt;/sub&gt;, MT&lt;sub&gt;2&lt;/sub&gt;, BDNF and GDNF mRNA were analyzed with RT-PCR. (2) Animals were separated into three groups with the first group receiving VPA (4 mg/mL), the second receiving VPA (3 mg/mL) for 16 days, and the control receiving vehicle. MT&lt;sub&gt;2&lt;/sub&gt; mRNA in the hippocampal subregions were analyzed with in situ hybridization.&lt;/p&gt; &lt;p&gt;VPA induced the expression of MT&lt;sub&gt;1&lt;/sub&gt; and MT&lt;sub&gt;2&lt;/sub&gt; mRNA in the hippocampus in the experimental group compared to the control group. VPA also increased MT&lt;sub&gt;2&lt;/sub&gt; mRNA expression in the subregions of the hippocampus. Additionally, BDNF and GDNF mRNA expression were increased in the VPA treatment group.&lt;/p&gt; &lt;p&gt;These findings raise the interesting question of whether the diverse clinical effects of VPA involve an interaction with the melatonergic system.&lt;/p&gt;","abstract_has_math":false,"creators":["Sathiyapalan, Arani"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":"Medical Sciences (Neuroscience and Behavioral Science)","school":null,"contributors":[],"advisors":["Niles, Len","Foster, Jane","Sakic, Boris"],"committee_chairs":[],"committee_members":[],"year":2013,"date_issued":"2013-04","date_published":"2013-04","updated_at":"2026-11-18T19:39:21Z","subjects":["Valproic acid","melatonin","melatonin receptors","GDNF","BDNF","HDAC inhibitor","epigenetic","in vivo","Molecular and Cellular Neuroscience","Neuroscience and Neurobiology"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://doi.org/10.71548/23175"],"render_values":[{"text":"https://doi.org/10.71548/23175","href":"https://doi.org/10.71548/23175","code":true}]},{"key":"dc:identifier.other","label":"Dc Identifier Other","values":["opendissertations/7748","8807","3995577"],"render_values":[{"text":"opendissertations/7748","href":null,"code":true},{"text":"8807","href":null,"code":true},{"text":"3995577","href":null,"code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/11375/12901","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"http://hdl.handle.net/11375/12901","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://macsphere.mcmaster.ca/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Amacsphere.mcmaster.ca%3A11375%2F12901","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Niles, Len","Foster, Jane","Sakic, Boris"]},{"key":"dc:contributor.department","label":"Department","values":["Medical Sciences (Neuroscience and Behavioral Science)"]},{"key":"dc:creator","label":"Author","values":["Sathiyapalan, Arani"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2014-06-18T17:01:11Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2014-06-18T17:01:11Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2013-04-04"]},{"key":"dc:date.issued","label":"Date","values":["2013-04"]},{"key":"dc:type","label":"Dc Type","values":["thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Valproic acid","melatonin","melatonin receptors","GDNF","BDNF","HDAC inhibitor","epigenetic","in vivo","Molecular and Cellular Neuroscience","Neuroscience and Neurobiology"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.other","label":"Dc Identifier Other","values":["opendissertations/7748","8807","3995577"]},{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/11375/12901","https://doi.org/10.71548/23175"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["<p>Valproic acid (VPA) is clinically utilized as an anti-convulsant and mood stabilizer, though its mechanism of action has not been fully elucidated.<strong> </strong>Evidence suggests an interaction between VPA and the melatonergic system as VPA up-regulated the melatonin MT<sub>1</sub> receptor subtype in rat C6 glioma cells. To determine if the observed effects can translate to an <em>in vivo </em>model, we investigated the effects of chronic VPA administration in a rat model on the expression of MT<sub>1</sub> and MT<sub>2</sub> receptors in the hippocampus. We also investigated the effect of chronic VPA treatment on the expression of the neurotrophic factors BDNF and GDNF in the rat hippocampus and striatum.</p> <p>(1) Animals were separated into two groups with the experimental group receiving VPA (4 mg/mL) for 17 days, and the control receiving vehicle. The hippocampus was dissected and MT<sub>1</sub>, MT<sub>2</sub>, BDNF and GDNF mRNA were analyzed with RT-PCR. (2) Animals were separated into three groups with the first group receiving VPA (4 mg/mL), the second receiving VPA (3 mg/mL) for 16 days, and the control receiving vehicle. MT<sub>2</sub> mRNA in the hippocampal subregions were analyzed with in situ hybridization.</p> <p>VPA induced the expression of MT<sub>1</sub> and MT<sub>2</sub> mRNA in the hippocampus in the experimental group compared to the control group. VPA also increased MT<sub>2</sub> mRNA expression in the subregions of the hippocampus. Additionally, BDNF and GDNF mRNA expression were increased in the VPA treatment group.</p> <p>These findings raise the interesting question of whether the diverse clinical effects of VPA involve an interaction with the melatonergic system.</p>"]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["Master of Science (MSc)"]},{"key":"dc:title","label":"Title","values":["EFFECTS OF VALPROIC ACID ON EXPRESSION OF THE MELATONIN RECEPTORS MT1 AND MT2, AND THE NEUROTROPHIC FACTORS BDNF AND GDNF IN VIVO"]},{"key":"others:access_status","label":"Others Access Status","values":["open.access"]}]}],"canonical_facts":{"dc:contributor.advisor":["Niles, Len","Foster, Jane","Sakic, Boris"],"dc:contributor.department":["Medical Sciences (Neuroscience and Behavioral Science)"],"dc:creator":["Sathiyapalan, Arani"],"dc:date.accessioned":["2014-06-18T17:01:11Z"],"dc:date.available":["2014-06-18T17:01:11Z"],"dc:date.created":["2013-04-04"],"dc:date.issued":["2013-04"],"dc:description.abstract":["<p>Valproic acid (VPA) is clinically utilized as an anti-convulsant and mood stabilizer, though its mechanism of action has not been fully elucidated.<strong> </strong>Evidence suggests an interaction between VPA and the melatonergic system as VPA up-regulated the melatonin MT<sub>1</sub> receptor subtype in rat C6 glioma cells. To determine if the observed effects can translate to an <em>in vivo </em>model, we investigated the effects of chronic VPA administration in a rat model on the expression of MT<sub>1</sub> and MT<sub>2</sub> receptors in the hippocampus. We also investigated the effect of chronic VPA treatment on the expression of the neurotrophic factors BDNF and GDNF in the rat hippocampus and striatum.</p> <p>(1) Animals were separated into two groups with the experimental group receiving VPA (4 mg/mL) for 17 days, and the control receiving vehicle. The hippocampus was dissected and MT<sub>1</sub>, MT<sub>2</sub>, BDNF and GDNF mRNA were analyzed with RT-PCR. (2) Animals were separated into three groups with the first group receiving VPA (4 mg/mL), the second receiving VPA (3 mg/mL) for 16 days, and the control receiving vehicle. MT<sub>2</sub> mRNA in the hippocampal subregions were analyzed with in situ hybridization.</p> <p>VPA induced the expression of MT<sub>1</sub> and MT<sub>2</sub> mRNA in the hippocampus in the experimental group compared to the control group. VPA also increased MT<sub>2</sub> mRNA expression in the subregions of the hippocampus. Additionally, BDNF and GDNF mRNA expression were increased in the VPA treatment group.</p> <p>These findings raise the interesting question of whether the diverse clinical effects of VPA involve an interaction with the melatonergic system.</p>"],"dc:description.degree":["Master of Science (MSc)"],"dc:identifier.other":["opendissertations/7748","8807","3995577"],"dc:identifier.uri":["http://hdl.handle.net/11375/12901","https://doi.org/10.71548/23175"],"dc:subject":["Valproic acid","melatonin","melatonin receptors","GDNF","BDNF","HDAC inhibitor","epigenetic","in vivo","Molecular and Cellular Neuroscience","Neuroscience and Neurobiology"],"dc:title":["EFFECTS OF VALPROIC ACID ON EXPRESSION OF THE MELATONIN RECEPTORS MT1 AND MT2, AND THE NEUROTROPHIC FACTORS BDNF AND GDNF IN VIVO"],"dc:type":["thesis"],"others:access_status":["open.access"]},"updated_at":"2026-11-18T19:39:21Z"}